• An Erratum to this article was published on 25 February 2015

This article has been updated


Antibiotic resistance is spreading faster than the introduction of new compounds into clinical practice, causing a public health crisis. Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s. Synthetic approaches to produce antibiotics have been unable to replace this platform. Uncultured bacteria make up approximately 99% of all species in external environments, and are an untapped source of new antibiotics. We developed several methods to grow uncultured organisms by cultivation in situ or by using specific growth factors. Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured bacteria. Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid). We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin. The properties of this compound suggest a path towards developing antibiotics that are likely to avoid development of resistance.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 21 January 2015

    Two minor typos were corrected in the main text and Methods.


Primary accessions


Data deposits

The biosynthetic gene cluster for teixobactin has been deposited with GenBank under accession number KP006601.


  1. 1.

    On the antibacterial action of cultures of a penicillium, with special reference to their use in the isolation of B. influenzae. Br. J. Exp. Pathol. 10, 226–236 (1929)

  2. 2.

    & Penicillin: the medicine with the greatest impact on therapeutic outcomes. Appl. Microbiol. Biotechnol. 92, 677–687 (2011)

  3. 3.

    , & Streptomycin, a substance exhibiting antibiotic activity against gram-positive and gram-negative bacteria. Proc. Soc. Exp. Biol. Med. 55, 66–69 (1944)

  4. 4.

    & Prioritized current unmet needs for antibacterial therapies. Clin. Pharmacol. Ther. 96, 151–153 (2014)

  5. 5.

    et al. Tackling antibiotic resistance. Nature Rev. Microbiol. 9, 894–896 (2011)

  6. 6.

    , , & Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nature Rev. Drug Discov. 6, 29–40 (2007)

  7. 7.

    Antibiotics: Recover the lost art of drug discovery. Nature 485, 439–440 (2012)

  8. 8.

    Platforms for antibiotic discovery. Nature Rev. Drug Discov. 12, 371–387 (2013)

  9. 9.

    , & Isolating “uncultivable” microorganisms in pure culture in a simulated natural environment. Science 296, 1127–1129 (2002)

  10. 10.

    et al. Use of ichip for high-throughput in situ cultivation of “uncultivable” microbial species. Appl. Environ. Microbiol. 76, 2445–2450 (2010)

  11. 11.

    et al. Siderophores from neighboring organisms promote the growth of uncultured bacteria. Chem. Biol. 17, 254–264 (2010)

  12. 12.

    et al. Lassomycin, a ribosomally synthesized cyclic peptide, kills Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem. Biol. 21, 509–518 (2014)

  13. 13.

    et al. An environmental bacterial taxon with a large and distinct metabolic repertoire. Nature 506, 58–62 (2014)

  14. 14.

    et al. Short peptide induces an “uncultivable” microorganism to grow in vitro. Appl. Environ. Microbiol. 74, 4889–4897 (2008)

  15. 15.

    et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42, 2398–2402 (2004)

  16. 16.

    Limitations of vancomycin in the management of resistant staphylococcal infections. Clin. Infect. Dis. 45 (Suppl 3). S191–S195 (2007)

  17. 17.

    , , & Quantitative analysis of the metabolism of soluble cytoplasmic peptidoglycan precursors of glycopeptide-resistant enterococci. Mol. Microbiol. 21, 33–44 (1996)

  18. 18.

    et al. Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA. Biochemistry 30, 10408–10415 (1991)

  19. 19.

    , , & d-Ala-d-Ala ligases from glycopeptide antibiotic-producing organisms are highly homologous to the enterococcal vancomycin-resistance ligases VanA and VanB. Proc. Natl Acad. Sci. USA 94, 6480–6483 (1997)

  20. 20.

    et al. Lesions in teichoic acid biosynthesis in Staphylococcus aureus lead to a lethal gain of function in the otherwise dispensable pathway. J. Bacteriol. 188, 4183–4189 (2006)

  21. 21.

    & Induction of autolysis of staphylococci by the basic peptide antibiotics Pep 5 and nisin and their influence on the activity of autolytic enzymes. Arch. Microbiol. 141, 249–254 (1985)

  22. 22.

    & Staphylococcus aureus capsular polysaccharides. Clin. Microbiol. Rev. 17, 218–234 (2004)

  23. 23.

    & Mutations blocking side chain assembly, polymerization, or transport of a Wzy-dependent Streptococcus pneumoniae capsule are lethal in the absence of suppressor mutations and can affect polymer transfer to the cell wall. J. Bacteriol. 189, 3369–3381 (2007)

  24. 24.

    et al. Transcription inhibition by the depsipeptide antibiotic salinamide A. eLife 3, e02451 (2014)

  25. 25.

    et al. A roadmap for natural product discovery based on large-scale genomics and metabolomics. Nature Chem. Biol. 10, 963–968 (2014)

  26. 26.

    et al. Bacterial phylogeny structures soil resistomes across habitats. Nature 509, 612–616 (2014)

  27. 27.

    et al. Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503, 365–370 (2013)

  28. 28.

    & An oldie but a goodie—cell wall biosynthesis as antibiotic target pathway. Int. J. Med. Microbiol. 300, 161–169 (2010)

  29. 29.

    , , & Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N. Engl. J. Med. 319, 157–161 (1988)

  30. 30.

    et al. Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and inhibition of cell wall biosynthesis for potent antibiotic activity. J. Biol. Chem. 276, 1772–1779 (2001)

  31. 31.

    et al. An alternative bactericidal mechanism of action for lantibiotic peptides that target lipid II. Science 313, 1636–1637 (2006)

  32. 32.

    et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 328, 1168–1172 (2010)

  33. 33.

    , & Review and re-analysis of domain-specific 16S primers. J. Microbiol. Methods 55, 541–555 (2003)

  34. 34.

    et al. The RAST Server: rapid annotations using subsystems technology. BMC Genomics 9, 75 (2008)

  35. 35.

    , & Standard operating procedure for calculating genome-to-genome distances based on high-scoring segment pairs. Stand. Genomic Sci. 2, 142–148 (2010)

  36. 36.

    , , & Digital DNA–DNA hybridization for microbial species delineation by means of genome-to-genome sequence comparison. Stand. Genomic Sci. 2, 117–134 (2010)

  37. 37.

    , , & Genome sequence-based species delimitation with confidence intervals and improved distance functions. BMC Bioinformatics 14, 60 (2013)

  38. 38.

    et al. NRPSpredictor2–a web server for predicting NRPS adenylation domain specificity. Nucleic Acids Res. 39, W362–W367 (2011)

  39. 39.

    et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. Antimicrob. Agents Chemother. 52, 1597–1603 (2008)

  40. 40.

    , , & Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49, 4210–4219 (2005)

  41. 41.

    , & Minimal inhibitory and mutant prevention concentrations of azithromycin, clarithromycin and erythromycin for clinical isolates of Streptococcus pneumoniae. J. Antimicrob. Chemother. 68, 631–635 (2013)

  42. 42.

    et al. The lipopeptide antibiotic Friulimicin B inhibits cell wall biosynthesis through complex formation with bactoprenol phosphate. Antimicrob. Agents Chemother. 53, 1610–1618 (2009)

  43. 43.

    , , & The lantibiotic mersacidin inhibits peptidoglycan biosynthesis at the level of transglycosylation. Eur. J. Biochem. 246, 193–199 (1997)

  44. 44.

    , , , & Interaction of type A lantibiotics with undecaprenol-bound cell envelope precursors. Microb. Drug Resist. 18, 261–270 (2012)

  45. 45.

    et al. In vitro assembly of a complete, pentaglycine interpeptide bridge containing cell wall precursor (lipid II-Gly5) of Staphylococcus aureus. Mol. Microbiol. 53, 675–685 (2004)

  46. 46.

    , , & Identification of multiple genes encoding membrane proteins with undecaprenyl pyrophosphate phosphatase (UppP) activity in Escherichia coli. J. Biol. Chem. 280, 18689–18695 (2005)

  47. 47.

    , , & The bacA gene of Escherichia coli encodes an undecaprenyl pyrophosphate phosphatase activity. J. Biol. Chem. 279, 30106–30113 (2004)

  48. 48.

    et al. Bacterial cell wall. MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. Science 345, 220–222 (2014)

  49. 49.

    et al. Identification of FtsW as a transporter of lipid-linked cell wall precursors across the membrane. EMBO J. 30, 1425–1432 (2011)

  50. 50.

    & The tagGH operon of Bacillus subtilis 168 encodes a two-component ABC transporter involved in the metabolism of two wall teichoic acids. Mol. Microbiol. 16, 345–355 (1995)

Download references


This work was supported by NIH grant T-RO1 AI085585 to K.L., by NIH grant AI085612 to A.L.S., by the Charles A. King Trust to B.P.C., and by the German Research Foundation (DFG; SCHN1284/1-2) and the German Center for Infection Research (DZIF) to T.S. and I.E. The NRS strains were provided by the Network on Antimicrobial Resistance in Staphylococcus aureus for distribution by BEI Resources, NIAID, NIH. Preclinical Services offered by NIAID are gratefully acknowledged. We thank H. G. Sahl for reading the manuscript and making comments, A. Makriyannis for suggestions, P. Muller, B. Berdy and S. Kaluziak for taxonomy analysis, and M. Josten for performing mass spectrometry analysis.

Author information

Author notes

    • Losee L. Ling
    •  & Tanja Schneider

    These authors contributed equally to this work.


  1. NovoBiotic Pharmaceuticals, Cambridge, Massachusetts 02138, USA

    • Losee L. Ling
    • , Aaron J. Peoples
    • , Amy L. Spoering
    • , Dallas E. Hughes
    • , Douglas R. Cohen
    • , Cintia R. Felix
    • , K. Ashley Fetterman
    • , William P. Millett
    • , Anthony G. Nitti
    •  & Ashley M. Zullo
  2. Institute of Medical Microbiology, Immunology and Parasitology—Pharmaceutical Microbiology Section, University of Bonn, Bonn 53115, Germany

    • Tanja Schneider
    • , Ina Engels
    •  & Anna Mueller
  3. German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne, 53115 Bonn, Germany

    • Tanja Schneider
    • , Ina Engels
    • , Anna Mueller
    •  & Till F. Schäberle
  4. Antimicrobial Discovery Center, Northeastern University, Department of Biology, Boston, Massachusetts 02115, USA

    • Brian P. Conlon
    • , Chao Chen
    •  & Kim Lewis
  5. Institute for Pharmaceutical Biology, University of Bonn, Bonn 53115, Germany

    • Till F. Schäberle
  6. Department of Biology, Northeastern University, Boston, Massachusetts 02115, USA

    • Slava Epstein
  7. Selcia, Ongar, Essex CM5 0GS, UK

    • Michael Jones
    • , Linos Lazarides
    •  & Victoria A. Steadman


  1. Search for Losee L. Ling in:

  2. Search for Tanja Schneider in:

  3. Search for Aaron J. Peoples in:

  4. Search for Amy L. Spoering in:

  5. Search for Ina Engels in:

  6. Search for Brian P. Conlon in:

  7. Search for Anna Mueller in:

  8. Search for Till F. Schäberle in:

  9. Search for Dallas E. Hughes in:

  10. Search for Slava Epstein in:

  11. Search for Michael Jones in:

  12. Search for Linos Lazarides in:

  13. Search for Victoria A. Steadman in:

  14. Search for Douglas R. Cohen in:

  15. Search for Cintia R. Felix in:

  16. Search for K. Ashley Fetterman in:

  17. Search for William P. Millett in:

  18. Search for Anthony G. Nitti in:

  19. Search for Ashley M. Zullo in:

  20. Search for Chao Chen in:

  21. Search for Kim Lewis in:


K.L. and T.S. designed the study, analysed results, and wrote the paper. L.L.L. designed the study and analysed results. A.J.P. designed the study, performed compound isolation and structure determination and analysed data. B.P.C. designed the study, performed susceptibility experiments and wrote the paper. D.E.H. oversaw preclinical work including designing studies and analysing data. S.E. designed cultivation experiments and analysed data. M.J., L.L. and V.A.S. designed and performed experiments on structure determination and analysed data. I.E. and A.M. designed and performed experiments on mechanism of action. A.L.S., D.R.C., C.R.F., K.A.F., W.P.M., A.G.N., A.M.Z. and C.C. performed experiments on compound production, isolation, susceptibility testing and data analysis. T.F.S. identified the biosynthetic cluster.

Competing interests

The following authors, L. L. Ling, A. J. Peoples, A. L. Spoering, D. E. Hughes, D. R. Cohen, C. R. Felix, K. A. Fetterman, W. P. Millett, A. G. Nitti, A. M. Zullo, K. Lewis, and S. Epstein, declare competing financial interests as they are employees and consultants of NovoBiotic Pharmaceuticals.

Corresponding author

Correspondence to Kim Lewis.

Extended data

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains a Supplementary Discussion.

About this article

Publication history






Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.